TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25847900
Drug: cinacalcet in
Normalized name: Product containing cinacalcet in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cinacalcet in combination with potassium citrate and allopurinol
Study: 23556995
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy only (Control group)
Study: 21410125
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (150 mL of 300 mg ropivacaine, 30 mg ketorolac, and 500 μg epinephrine) with an additional 100 mg ropivacaine on postoperative day 1.
Study: 21410125
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with a single‐shot femoral nerve block (150 mg of ropivacaine with epinephrine).
Study: 16902175
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy on music (same amount as whole-body vibration)
Study: 12782920
Drug: Ganstigmine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganstigmine 12.5 mg
Study: 12782920
Drug: Ganstigmine 10
Normalized name: Ganstigmine
DrugBank: Ganstigmine (DB06525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganstigmine 10 mg
Study: 12782920
Drug: Ganstigmine (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganstigmine (5, 7.5, 10 mg)
Study: 12782920
Drug: Ganstigmine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganstigmine (all doses)
Study: 11048830
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (60 mg daily from 24 weeks' gestation through delivery)
Study: 11048830
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (60 mg daily from 24 weeks' gestation through delivery) and Placebo
Study: 9091506
Drug: 0.05% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tretinoin emollient cream (Renova, Retinova)
Study: 9091506
Drug: 0.05% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tretinoin emollient cream (Renova, Retinova) continued for another 6 months
Study: 2279256
Drug: Ibopamine 200
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 200 mg b.i.d.
Study: 8225657
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg q.d.
Study: 3703495
Drug: Intravitreal thrombin
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal thrombin (100 units/ml)
Study: 20169667
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus carboplatin (TC) therapy: 180 mg/m2 paclitaxel on day 1 plus AUC 6 mg/mL x minute carboplatin on day 1 every 21 days
Study: 20169667
Drug: Irinotecan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan plus cisplatin (CPT-P) therapy: 60 mg/m2 irinotecan hydrochloride on days 1, 8, 15 plus 60 mg/m2 cisplatin on day 1 every 28 days
Study: 7527108
Drug: Nifedipine slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine slow-release (SR) 20 mg twice daily
Study: 7527108
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of trandolapril and nifedipine SR
Study: 26412801
Drug: Higher-bioavailability BNX
Normalized name: BNX
DrugBank: Oxybuprocaine (DB00892)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-bioavailability BNX sublingual tablet
Study: 19556972
Drug: Aliskiren combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren combination therapy
Study: 19556972
Drug: Aliskiren monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren monotherapy or combination therapy
Study: 15517078
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg three times daily for 4 weeks)
Study: 11781669
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A (200,000 IU) on admission and placebo daily until discharge
Study: 11781669
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin A (5,000 IU) daily from admission until discharge
Study: 11781669
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily from admission until discharge
Study: 9264493
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg BID)
Study: 31503155
Drug: Nitrofurantoin 100
Normalized name: nitrofurantoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin 100 mg daily
Study: 25346093
Drug: Calcipotriol/betamethasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol/betamethasone dipropionate topical gel (once daily for 8 weeks)
Study: 15253730
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment (erythropoietin initiated when hemoglobin <9 g/dL)
Study: 9385487
Drug: Once-daily (QD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily (QD) formulation of loratadine 10 mg and pseudoephedrine sulfate 240 mg
Study: 8100153
Drug: UDCA 600
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 600 mg/day for 3 months
Study: 8100153
Drug: Long-term UDCA
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term UDCA treatment (mean 20 months)
Study: 17907263
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ST zolpidem
Study: 14663041
Drug: riluzole 200
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: riluzole 200 mg/day
Study: 8864970
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment mainly using spinal manipulation
Study: 1378155
Drug: Carvedilol (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25-50 mg once daily, starting at 12.5 mg for 2 days)
Study: 14751571
Drug: GLP-2 injection
Normalized name: (Gly2)GLP-2
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GLP-2 injection
Study: 26993372
Drug: Moderate ibudilast
Normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Moderate ibudilast (40 mg)
Study: 26993372
Drug: High-dose ibudilast
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ibudilast (100 mg)
Study: 23163191
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (7vPCV) administered at ages 0, 1, and 2 months or at 1, 2, and 3 months
Study: 8857017
Drug: Cardiac troponin
Normalized name: Cardiac troponin I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac troponin I levels of at least 0.4 ng/mL
Study: 8857017
Drug: Cardiac troponin
Normalized name: Cardiac troponin I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac troponin I levels below 0.4 ng/mL
Study: 8857017
Drug: Increase of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase of 1 ng/mL in cardiac troponin I level
Study: 1764383
Drug: Early stage
Normalized name: SALICYLIC ACID 0.14 mg TOPICAL PATCH [Peace Out Early Stage Acne Dot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early stage protocol (adjuvant therapy)
Study: 113810
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 1 week
Study: 17725246
Drug: Moxonidine, 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine, 0.6 mg/day
Study: 9153445
Drug: Dextromethorphan (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (mean dose 381 mg/day)
Study: 24612502
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg/day) plus letrozole (2.5 mg/day)
Study: 29654415
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus letrozole (2.5 mg/day)
Study: 9316528
Drug: Losartan 25
Normalized name: LOSARTAN 25MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 25 mg/day
Study: 29092886
Drug: 2RDA (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2RDA (1.6 g protein · kg‐1 · d‐1)
Study: 19297572
Drug: CMV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV vaccine (recombinant CMV envelope glycoprotein B with MF59 adjuvant)
Study: 17144474
Drug: Xiaozheng pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaozheng pills
Study: 29356022
Drug: Optical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optical treatment with corrective lenses based on cycloplegic refraction for amblyopia
Study: 29356022
Drug: Optical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optical treatment
Study: 26165528
Drug: Non-rebreather mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-rebreather mask (NRB) at 15 L·min⁻¹
Study: 18182467
Drug: PE +
Normalized name: Chlorpheniramine Maleate/Phenylephrine Hydrochloride 4 MG-10 MG Oral Tablet [SINUS PE + ALLERGY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE + F + D (both type I and type II agonists)
Study: 12855334
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (NGF) injection (5 microg in 0.2 ml) into the masseter muscle
Study: 12855334
Drug: Buffered isotonic
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered isotonic saline injection into the masseter muscle
Study: 8708517
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate 2 mg/day for 21 days and Norgestrel 0.5 mg/day from day 12 to 21 for the first 8 weeks, followed by placebo for the last 8 weeks
Study: 6814471
Drug: BHT 933
Normalized name: BHT
DrugBank: Butylated hydroxytoluene (DB16863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHT 933 (5 mg)
Study: 6814471
Drug: BHT 933
Normalized name: BHT
DrugBank: Butylated hydroxytoluene (DB16863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHT 933 (10 mg)
Study: 28542675
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous acetaminophen (IVAPAP)
Study: 28542675
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mL saline infusion)
Study: 23343675
Drug: Bing sweet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bing sweet cherries (280 g/d) for 28 days
Study: 20056649
Drug: Calcium (2
Normalized name: calcium (2ξ)-D-gluco-heptonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (2 g/d)
Study: 19359985
Drug: Theophylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (200 to 800 mg daily for 2- to 8-month periods)
Study: 22475307
Drug: Food associated
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food associated with familiar characters (e.g., sugary or salty snacks)
Study: 20353747
Drug: Clopidogrel besylate
Normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel besylate (test formulation)
Study: 20353747
Drug: Clopidogrel bisulfate
Normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel bisulfate (reference formulation)
Study: 19027436
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo exposure therapy
Study: 23796315
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality exposure therapy
Study: 12520629
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (4.5 g) administered after an overnight fast
Study: 12520629
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (4.5 g) administered after a high-fat meal
Study: 11574436
Drug: Hypoglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (blood glucose 2.59 [0.19] mmol/l)
Study: 3662586
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 200 micrograms twice daily
Study: 21612468
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg) with prednisone (5 mg twice daily)
Study: 21612468
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with prednisone (5 mg twice daily)
Study: 19218816
Drug: Omalizumab administered
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab administered subcutaneously every 2 or 4 weeks based on serum IgE level and body weight.
Study: 9770887
Drug: Anti Hp
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti Hp IgG antibodies
Study: 1251775
Drug: Streptokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase and heparin
Study: 28235531
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (1mg/kg) of propofol and normoventilation (ETCO2 of 40‐45mmHg) (group P/N)
Study: 28235531
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose (0.5mg/kg) of propofol with divided remifentanil injections and normoventilation (group RP/N)
Study: 19563190
Drug: Fire-needle therapy
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire-needle therapy
Study: 16641466
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of ermB, ermTR, and mefA/E antibiotic resistance genes
Study: 11380515
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E therapy
Study: 7521724
Drug: Hepatic resection
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic resection after IL-2 therapy
Study: 16567830
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg/day for 24 weeks
Study: 11570313
Drug: Monthly combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly combination injectable contraceptive (estradiol cypionate and medroxyprogesterone acetate)
Study: 3045028
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride 1 g twice/day
Study: 27009057
Drug: Tailored behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored behavioural medicine treatment
Study: 22999398
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg enantiomeric excess hyperbaric levobupivacaine
Study: 2611360
Drug: Flurbiprofen with
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen with Maalox (antacid)
Study: 2611360
Drug: Flurbiprofen every
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen every 12 h from Day 3 to Day 8 with Maalox (antacid)
Study: 6740281
Drug: Duck embryo
Normalized name: Duck
DrugBank: Duck (DB10610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duck embryo rabies vaccine (DEV)
Study: 21415046
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) with fluoxetine if indicated, 20 sessions over 18 weeks
Study: 21415046
Drug: Stepped-care approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care approach starting with supervised self-help, with fluoxetine added if non-responders after 6 sessions, followed by CBT if needed
Study: 14716714
Drug: Glucose (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (four 3 mg dextrose tablets)
Study: 14716714
Drug: Placebo (sorbitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sorbitol tablets)
Study: 9581743
Drug: Ibutilide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (1 mg IV infusion, two 10-min infusions)
Study: 9581743
Drug: Procainamide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (400 mg IV infusion, three successive 10-min infusions)
Study: 16963472
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg/day
Study: 18950770
Drug: Perindopril 8
Normalized name: perindopril 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 8 mg/day
Study: 1937372
Drug: Ranitidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (400 mg b.i.d.)
Study: 23785050
Drug: Enoxaparin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 0.5 mg/kg bolus intravenously 10 to 15 minutes before procedure, followed by 40 mg once daily for 7 days in low-risk group.
Study: 23785050
Drug: Enoxaparin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 0.5 mg/kg bolus intravenously 10 to 15 minutes before procedure, followed by 1 mg/kg subcutaneously 2 times a day for 48 hours, then 40 mg once daily for 5 days in high-risk group.
Study: 21899708
Drug: 2.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% lidocaine plus 2.5% prilocaine cream (n = 46)
Study: 18779616
Drug: Clodronate, 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate, 1.6 g orally administered daily
Study: 29766635
Drug: MK-1293 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1293 insulin glargine (Mk-Gla; 100 U/mL)
Study: 29766635
Drug: Originator insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Originator insulin glargine (Lantus; Sa-Gla)
Study: 29761615
Drug: MK-1293 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1293 insulin glargine (Mk-Gla)
Study: 24910399
Drug: Knee stabilization
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee stabilization therapy prior to strength/functional training
Study: 24910399
Drug: Control programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control programme (without knee stabilization therapy)
Study: 8288727
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg bid)
Study: 11720425
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no further treatment)
Study: 27486878
Drug: PF induction
Normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF induction chemotherapy
Study: 24962480
Drug: Oligonol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligonol (200 mg daily for 1 week)
Study: 21167471
Drug: Tinidazole 500
Normalized name: tinidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 500 mg twice daily
Study: 21167471
Drug: Tinidazole 1
Normalized name: tinidazole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 1 g twice daily
Study: 11719823
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized estradiol substitution (Group I)
Study: 16715674
Drug: 24 g
Normalized name: glucose 24 g/31 g oral gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 g iodine
Study: 16715674
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g iodine
Study: 8299830
Drug: Computed radiography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computed radiography with a photostimulable storage phosphor (50% radiation dose)
Study: 8299830
Drug: Computed radiography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computed radiography with a photostimulable storage phosphor (10% radiation dose)
Study: 8299830
Drug: Conventional calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional calcium tungstate screen‐film combination (100% radiation dose)
Study: 27559716
Drug: ω‐3 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 plus capsules
Study: 20077006
Drug: Assertive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive community treatment (ACT) without IMR
Study: 19202956
Drug: Long-acting β-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting β-agonists (LABAs) with inhaled corticosteroid (ICS)
Study: 12672582
Drug: Chloramphenicol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (75 mg/kg per day, max 2 g/day, in four doses for 14 days)
Study: 1514339
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg/kg
Study: 1992843
Drug: Transdermally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermally administered nicotine
Study: 31916033
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement with immediate provisionalization (TG)
Study: 31916033
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) with immediate implants with intact alveoli
Study: 22623016
Drug: Tramadol (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (350 mg)
Study: 22623016
Drug: Hydromorphone (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (16 mg)
Study: 15747762
Drug: Early retinal
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early retinal ablative treatment
Study: 11709366
Drug: Amprenavir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir with saquinavir soft gel capsule
Study: 9046304
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg per day tirilazad
Study: 9046304
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg per day tirilazad
Study: 9046304
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including placebo and both doses of tirilazad)